New York, NY -- (SBWIRE) -- 12/24/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: LDK Solar Co., Ltd (ADR) (NYSE:LDK), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), Amarin Corporation plc (ADR) (NASDAQ:AMRN), Frontier Communications Corp (NASDAQ:FTR),
LDK Solar Co., Ltd (ADR) (NYSE:LDK) showed a volume of 1.16 million shares by the end of last trade whereas the average volume of the stock remained 1.63 million shares. The stock opened the session at $1.35 but then moved to $1.31. At that price, the stock showed a negative performance of -2.96%. LDK Solar Co., Ltd. is a vertically integrated manufacturer of Photovoltaic (PV) products. The Company’s products include Polysilicon, Solar Wafers, Solar Cells, Solar Modules and Solar Farm Projects. It operates in two segments: Polysilicon and Other PV products. Polysilicon segment involves the production and sales of polysilicon. Other PV products segment involves the manufacture and sales of monocrystalline and multicrystalline solar wafers and PV modules and processing services, manufacture and sales of PV cells and the development of power plant projects.
Will LDK Get Buyers Even After The Recent Rally? Find Out Here
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) opened the session at $2.07 and closed the session at $2.05. Traded with volume of 1.05 million shares in the prior session and the average volume of the stock remained 1.71 million shares. Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company’s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent.
Is NAVB a Solid Investment at These Levels? Read This Report For Details
Amarin Corporation plc (ADR) (NASDAQ:AMRN) opened the session at $2.10 and closed the session at $1.92. The stock showed a negative performance of -3.76% in previous trading session. Traded with volume of 9.84 million shares in the prior session and the average volume of the stock remained 5.44 million shares. The beta of the stock remained 1.08. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101,
Why Should Investors Buy AMRN After the Recent Fall? Just Go Here and Find Out
Frontier Communications Corp (NASDAQ:FTR) traded with volume of 6.66 million shares in the prior session and the average volume of the stock remained 11.57 million shares. The beta of the stock remained 0.70. Frontier Communications Corporation (Frontier) is a communications company providing services primarily to rural areas and small and medium-sized towns and cities in the United States. The Company offers a range of voice, data, Internet, and television services and products, some that are available a la carte, and others that are available as bundled or packaged solutions. It operated in 27 states, and was the Incumbent Local Exchange Carrier (ILEC), with approximately 5.3 million access lines and 1.8 million broadband connections as of December 31, 2011.
Is FTR a Solid Investment at These Levels? Read This Report For Details
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)